Expression of CD99 in pleomorphic carcinomas of the lung.
Pleomorphic carcinoma of the lung (PCL) is characterized by a mixture of sarcomatoid and carcinoma components, and a poor prognosis. However, no immunophenotype of tumor markers has been characterized in PCL. To characterize the immunophenotype for CD99 in PCL, we performed an immunohistochemical evaluation of PCLs for thyroid transcription factor-1 (TTF-1), cytokeratin (CK) 7 and 20, and for CD99. CD99 was found to be expressed in both carcinomatous (47%) and sarcomatous components such as spindle cells (92%) and giant cells (57%). In the case of spindle cells, CK7 was expressed in 6 cases (46%) and TTF-1 in 2 cases (15%), whereas for giant cells CK7 was expressed in 8 cases (57%) and TTF-1 in one case (7%). However, CK20 was not expressed in either the carcinomatous or sarcomatous components in any case. Thus, CD99 was found to be widely expressed in both sarcomatous and carcinoma component in PCL. A clinicopathological analysis showed no direct correlation between the expression of CD99 and the clinical indices (stage, survival rate, invasion) of PCL.
Yoo
Seong-Ho
SH
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Han
Jungho
J
Kim
Tae Jin
TJ
Chung
Doo Hyun
DH
D000071443:12E7 Antigen; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000096:biosynthesis*; D002277:Carcinoma / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D007381:Intermediate Filament Proteins / Q000096:biosynthesis; D053554:Keratin-20; D053552:Keratin-7; D007633:Keratins / Q000096:biosynthesis; D008175:Lung Neoplasms / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000096:biosynthesis; D011379:Prognosis; D012509:Sarcoma / Q000378:metabolism; D000074482:Thyroid Nuclear Factor 1; D013997:Time Factors; D014157:Transcription Factors / Q000096:biosynthesis
D000071443:12E7 Antigen; D015703:Antigens, CD; C061828:CD99 protein, human; D015815:Cell Adhesion Molecules; D007381:Intermediate Filament Proteins; C507499:KRT20 protein, human; C507497:KRT7 protein, human; D053554:Keratin-20; D053552:Keratin-7; C000614412:NKX2-1 protein, human; D009687:Nuclear Proteins; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors; D007633:Keratins
Lung Cancer. 2001 Oct;34(1):91-7
11557118
Cancer. 1999 Aug 15;86(4):608-16
10440688
Mod Pathol. 2001 Nov;14(11):1175-82
11706081
Eur Respir J. 2001 Dec;18(6):1059-68
11829087
Clin Chest Med. 2002 Mar;23(1):65-81, viii
11901921
Am J Surg Pathol. 2002 Apr;26(4):510-6
11914631
J Korean Med Sci. 2002 Aug;17(4):483-9
12172043
Exp Mol Med. 2002 Jul 31;34(3):177-83
12216109
Am J Surg Pathol. 2003 Mar;27(3):311-24
12604887
Int J Hematol. 2003 May;77(4):330-5
12774919
FEBS Lett. 2003 Nov 20;554(3):478-84
14623115
Exp Mol Med. 2003 Oct 31;35(5):438-47
14646598
Cancer. 1976 May;37(5):2275-82
1260715
J Pathol. 1985 Dec;147(4):291-301
2418184
Oncogene. 1990 Jul;5(7):1067-70
1695726
Cancer. 1991 Apr 1;67(7):1886-93
1848471
Hum Pathol. 1992 Feb;23(2):197-200
1740306
Am J Surg Pathol. 1994 May;18(5):486-94
7513503
Cancer. 1994 Jun 15;73(12):2936-45
8199991
N Engl J Med. 1994 Aug 4;331(5):294-9
8022439
Am J Clin Pathol. 1994 Sep;102(3):331-40
8085557
Virchows Arch. 2000 Sep;437(3):270-4
11037347
Cancer. 1995 Jan 1;75(1 Suppl):191-202
8000996
Semin Diagn Pathol. 1995 May;12(2):123-39
7638446
Am J Surg Pathol. 1996 Mar;20(3):277-85
8772780
Hum Pathol. 1996 Dec;27(12):1273-6
8958297
Am J Surg Pathol. 1997 Jul;21(7):801-11
9236836
Hum Pathol. 1997 Nov;28(11):1247-54
9385929
Histopathology. 1998 Mar;32(3):225-31
9568507
Hum Pathol. 1998 Aug;29(8):840-5
9712426
Mod Pathol. 1998 Aug;11(8):769-73
9720506
Blood. 1998 Dec 1;92(11):4287-95
9834235
Am J Pathol. 1998 Dec;153(6):1937-45
9846983
Ann Diagn Pathol. 1998 Dec;2(6):401-21
9930576
Virchows Arch. 1999 May;434(5):443-9
10389628
Leuk Lymphoma. 2001 Aug;42(4):587-94
11697486